tradingkey.logo

BRIEF-FDA Recommends Changes To Labeling For Transmucosal Buprenorphine Products Indicated To Treat Opioid Use Disorder

ReutersDec 26, 2024 5:11 PM

- FDA:

  • FDA: RECOMMENDS CHANGES TO LABELING FOR TRANSMUCOSAL BUPRENORPHINE PRODUCTS INDICATED TO TREAT OPIOID USE DISORDER - WEBSITE

  • FDA: RECOMMENDED CHANGES INTEND TO CLARIFY THAT NEITHER 16 MG/DAY NOR 24 MG/DAY SHOULD BE INTERPRETED AS MAXIMUM DOSAGES FOR BTODS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI